Author

Brett M. Stevens

University of Colorado AnschutzORCID 0000-0002-9346-903XUnclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Cancer Biology· 3

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 3 Approach:experimental assay· 3 Organism:human· 3 Research Focus:cancer & tumor microenvironment· 2 Research Focus:cell type annotation· 2 Research Focus:differential expression· 2 Research Focus:cell signaling & trafficking· 1 Research Focus:drug response / drug discovery· 1

Frequent Co-Authors

Ana VujoviciD· 2 shared Angelo D’AlessandroiD· 2 shared Austin E. GilleniD· 2 shared Craig T. JordaniD· 2 shared Daniel StephensoniD· 2 shared Mark Jordan AlthoffiD· 2 shared Regan MilleriD· 2 shared Stephanie GipsoniD· 2 shared

Activity by Year

2025-2026 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

Ana VujovicORCID

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

The Nicotinamide Salvage Pathway is a Metabolic Vulnerability of High-Risk MDS Stem Cells

Sweta B. Patel, Daniel R Moskop, Steven Moreira, Stephanie Gipson, Colin C. Anderson, Alexandra A. Crook, Maxwell C. McCabe, Daniel Stephenson, Hannah E. Terry, Andrew Kent, Tracy N. Young, Anna E. Krug, Connon I. Thomas, Caitlin Price, Monica Ransom, , Eric Martin Pietras

This study identifies NAMPT as a metabolic vulnerability in HR-MDS HSPCs, showing its inhibition reduces their survival and disease burden.

Blood Cancer Discovery · Jul 17, 2026Peer-reviewedCancer Biology

Therapy resistance in AML is mediated by cytoplasmic sequestration of the transcriptional repressor IRF2BP2

Mark Jordan Althoff, Mohd Minhajuddin, Brett M. Stevens, Austin E. Gillen, Stephanie Gipson, Sweta B. Patel, Ian T. Shelton, Regan Miller, Ana Vujovic, Anna Krug, Tracy Young, William M. Showers, Monika Dzieciątkowska, Daniel Stephenson, Anit Tyagi, , Craig T. Jordan

This study identifies IRF2BP2 cytoplasmic sequestration by MCL1 as a mechanism driving venetoclax and azacitidine resistance in AML through ACSL1 derepression.

bioRxiv · May 22, 2025 · PreprintCancer Biology

Ribosome Profiling Reveals Translational Reprogramming via mTOR Activation in Omacetaxine Resistant Multiple Myeloma

Zachary J. Walker, Katherine F. Vaeth, Amber Baldwin, Denis J. Ohlstrom, Lauren T. Reiman, Kady A. Dennis, Kate Matlin, Beau M. Idler, Brett M. Stevens, Neelanjan Mukherjee, Daniel W. Sherbenou

This study identifies translational reprogramming via mTOR activation as a mechanism of omacetaxine resistance in multiple myeloma and suggests combination therapy with mTOR inhibitors.

Molecular Cancer Research · Mar 6, 2025Peer-reviewedCancer Biology